Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, Guangdong, China.
Department of Thoracic Surgery, The Third Clinical College of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China.
Sci Rep. 2022 Jun 27;12(1):10841. doi: 10.1038/s41598-022-14222-w.
Recombinant human endostatin (Endostar) plus vinorelbine/cisplatin (NP) had been approved for the treatment of non-small cell lung cancers (NSCLC). But the real-world treatment pattern and effectiveness of Endostar plus other combination chemotherapy, namely docetaxel/platinum (DP), gemcitabine/platinum (GP), pemetrexed/platinum (PP), and paclitaxel/platinum (TP) in both treatment-naïve and re-treatment patients with advanced NSCLC were still unclear. A retrospective observational study was conducted based on the electronic medical record (EMR) system and advanced patients with NSCLC were identified from 7 cancer hospitals in China from 2012 to 2019. These patients were divided into five groups, Endostar plus NP, Endostar plus DP, Endostar plus GP, Endostar plus PP, and Endostar plus TP groups. The disease control rate (DCR), overall response rate (ORR), and the progression-free survival (PFS) were evaluated. Of the eligible 512 advanced patients with NSCLC, 10.35% were in Endostar plus NP group, while the numbers were 15.43%, 32.42%, 26.56%, 15.23% in Endostar plus DP group, Endostar plus GP group, Endostar plus PP group, and Endostar plus TP group, respectively. The ORRs were 31%, 28%, 22%, 41% and 27%, and the DCRs were 71%, 72%, 57%, 72% and 76%, respectively. The median of PFSs for the above groups were 7.9, 6.8, 5.6, 13.7, and 5.4 months. Compared with Endostar plus NP group, the hazard ratios (HRs) and 95%CIs of Endostar plus other chemotherapy were 1.86 (0.75-4.61), 2.15 (0.83-5.60), 1.33 (0.51-3.44), and 2.42 (0.86-6.81). This real-world study found the effectiveness of Endostar plus DP, Endostar plus GP, Endostar plus PP, and Endostar plus TP were of no statistically significant differences compared with Endostar plus NP and reflected the good effectiveness of Endostar plus different chemotherapy in advanced patients with NSCLC.
重组人血管内皮抑制素（恩度）联合长春瑞滨/顺铂（NP）已被批准用于治疗非小细胞肺癌（NSCLC）。然而，在治疗初治和复治的晚期 NSCLC 患者中，恩度联合其他联合化疗方案（多西他赛/铂类（DP）、吉西他滨/铂类（GP）、培美曲塞/铂类（PP）和紫杉醇/铂类（TP））的实际治疗模式和有效性仍不清楚。本研究基于电子病历（EMR）系统开展了一项回顾性观察性研究，从中国 7 家癌症医院中确定了 2012 年至 2019 年期间的晚期 NSCLC 患者。这些患者被分为 5 组，分别为恩度联合 NP、恩度联合 DP、恩度联合 GP、恩度联合 PP 和恩度联合 TP 组。评估疾病控制率（DCR）、总缓解率（ORR）和无进展生存期（PFS）。在符合条件的 512 例晚期 NSCLC 患者中，恩度联合 NP 组占 10.35%，而恩度联合 DP 组、恩度联合 GP 组、恩度联合 PP 组和恩度联合 TP 组分别占 15.43%、32.42%、26.56%和 15.23%。ORR 分别为 31%、28%、22%、41%和 27%，DCR 分别为 71%、72%、57%、72%和 76%。上述各组的中位 PFS 分别为 7.9、6.8、5.6、13.7 和 5.4 个月。与恩度联合 NP 组相比，恩度联合其他化疗的风险比（HR）及其 95%CI 分别为 1.86（0.75-4.61）、2.15（0.83-5.60）、1.33（0.51-3.44）和 2.42（0.86-6.81）。这项真实世界的研究发现，与恩度联合 NP 相比，恩度联合 DP、恩度联合 GP、恩度联合 PP 和恩度联合 TP 的疗效无统计学差异，反映了恩度联合不同化疗方案在晚期 NSCLC 患者中的良好疗效。
